Joachim Eeckhout
@joachimeeckhout.bsky.social
Founder of Labiotech.eu and TheScienceMarketer.com | Mostly sharing biotech links (because I heard it's allowed here)
I didn't know that cancer cells could manipulate glycans to escape the immune system. Fascinating field emerging right now in #biotech.
#biosky #chemsky 🧪
#biosky #chemsky 🧪
Targeting sugar molecules: Can glycobiology lead to a new era for cancer immunotherapy?
Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.
www.labiotech.eu
December 12, 2024 at 3:26 PM
For people who are into #SciComm, this could be interesting
How to get started with thought leadership in science
The blueprint used by Kat Arney, chief creative office of First Create the Media
www.thesciencemarketer.com
November 26, 2024 at 3:05 PM
For people who are into #SciComm, this could be interesting
Reposted by Joachim Eeckhout
The FDA has approved BridgeBio's rare heart disease drug, notably including mortality on the label. BridgeBio will brand the drug as Attruby, and it will cost about $245K per year. $BBIO
endpts.com/fda-approves...
endpts.com/fda-approves...
FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam
The FDA approved BridgeBio’s acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost agains...
endpts.com
November 23, 2024 at 12:17 AM
The FDA has approved BridgeBio's rare heart disease drug, notably including mortality on the label. BridgeBio will brand the drug as Attruby, and it will cost about $245K per year. $BBIO
endpts.com/fda-approves...
endpts.com/fda-approves...
Reposted by Joachim Eeckhout
One way to track the # of patients treated w #CARTCell #immunotherapy is by sales, now on a $5 billion/year pace. h/t Bertrand Delsuc
November 22, 2024 at 12:41 PM
One way to track the # of patients treated w #CARTCell #immunotherapy is by sales, now on a $5 billion/year pace. h/t Bertrand Delsuc
Reposted by Joachim Eeckhout
‘A place of joy’: why scientists are joining the rush to Bluesky
For me, it certainly feels good to be here!
@natureportfolio.bsky.social @bsky.app
www.nature.com/articles/d41...
For me, it certainly feels good to be here!
@natureportfolio.bsky.social @bsky.app
www.nature.com/articles/d41...
‘A place of joy’: why scientists are joining the rush to Bluesky
Researchers say the social-media platform — an alternative to X — offers more control over the content they see and the people they engage with.
www.nature.com
November 22, 2024 at 6:49 AM
‘A place of joy’: why scientists are joining the rush to Bluesky
For me, it certainly feels good to be here!
@natureportfolio.bsky.social @bsky.app
www.nature.com/articles/d41...
For me, it certainly feels good to be here!
@natureportfolio.bsky.social @bsky.app
www.nature.com/articles/d41...
hi #bluesky, in case someone is interested in completely deleting their presence on the old site, you can use this tool for free: redact.dev
It works wonderfully!
It works wonderfully!
Mass delete your tweets posts & DMs on 30+ sites
Mass delete your Messages, Posts and Comments on over 30+ services.
redact.dev
November 22, 2024 at 9:10 AM
hi #bluesky, in case someone is interested in completely deleting their presence on the old site, you can use this tool for free: redact.dev
It works wonderfully!
It works wonderfully!
A good overview of where gene therapy is being applied #biotech 🧪
Eight areas where gene therapy shines
Delve into the numerous applications of gene therapy, from cancer to hematological disorders and respiratory diseases.
www.labiotech.eu
November 21, 2024 at 1:56 PM
A good overview of where gene therapy is being applied #biotech 🧪
Interesting news, from a Labiotech alumni reporter
FDA approves first-ever gene therapy to be directly administered to the brain
PTC Therapeutics has received FDA approval for a gene therapy to treat AADC deficiency, a rare genetic disorder that impairs the normal function of neurons.
www.biopharma-reporter.com
November 20, 2024 at 3:27 PM
Interesting news, from a Labiotech alumni reporter
The trending two-in-one approach in #biotech 🧪
Six bispecific antibody companies you should know about
Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.
www.labiotech.eu
November 20, 2024 at 12:35 PM
The trending two-in-one approach in #biotech 🧪
Reposted by Joachim Eeckhout
Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment from Gates Foundation to extend series A to $50M. www.prnewswire.com/news-release...
Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment
/PRNewswire/ -- Freya Biosciences (Freya or the Company), a transatlantic biotech company specializing in women's health, today announces a $10.4 million...
www.prnewswire.com
November 19, 2024 at 3:21 PM
Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment from Gates Foundation to extend series A to $50M. www.prnewswire.com/news-release...